1-((4-溴苯基)-(4-氯苯基))甲醇 | 105901-10-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-((4-溴苯基)-(4-氯苯基))甲醇
• 中文别名: 苯甲醇,4-溴-a-(4-氯苯基)-
• 英文名称: 1-((4-bromophenyl)-(4-chlorophenyl))methanol
• 英文别名: (4-bromophenyl)(4-chlorophenyl)methanol；4-bromo-4'-chloro-benzhydrol；(+/-)-Hydroxy-(4-chlor-phenyl)-(4-brom-phenyl)-methan；4-Brom-4'-chlor-benzhydrol；(+/-)-(4-Chlor-phenyl)-(4-brom-phenyl)-methanol；(4-bromophenyl)-(4-chlorophenyl)methanol
• CAS: 105901-10-8
• 化学式: C₁₃H₁₀BrClO
• mdl: MFCD12783948
• 分子量: 297.579
• InChiKey: LJKBUKUTDSVGIX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.076
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-((4-溴苯基)-(4-氯苯基))甲醇 在 tris(dibenzylideneacetone)dipalladium (0) 偶氮二甲酸二异丙酯 、 potassium acetate 、 三苯基膦 、 三环己基膦 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 34.0h， 生成 2-((4-chlorophenyl)(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methyl)isoindoline-1,3-dione
  参考文献：
  名称：

  通过基于结构的设计，蛋白激酶B的6-苯基嘌呤抑制剂快速发展。

  摘要：

  从基于片段的筛选中，6-苯基嘌呤被鉴定为新型的，具有ATP竞争性的蛋白激酶B（PKB / Akt）抑制剂，并通过使用PKA-PKB嵌合蛋白的迭代蛋白-配体结晶技术，迅速发展为有效的化合物。精心制作的先导化合物显示出细胞生长抑制作用，并对PKB抑制特性的细胞信号通路产生影响。

  DOI：

  10.1021/jm0700924
• 作为产物：
  描述：

  4-溴-4-氯二苯甲酮 在 aluminum isopropoxide 、 异丙醇 作用下， 生成 1-((4-溴苯基)-(4-氯苯基))甲醇
  参考文献：
  名称：

  UNSYMMETRICALLY DISUBSTITUTED PIPERAZINES. III. N-METHYL-N'-BENZHYDRYLPIPERAZINES AS HISTAMINE ANTAGONISTS¹

  摘要：

  DOI：

  10.1021/jo01157a009

文献信息

• A NOVEL SYNTHESIS OF SOME MIXED ARYLMETHYL–ALKYL ETHERS
  作者：K. G. Rutherford、O. A. Mamer、J. M. Prokipcak、R. A. Jobin

  DOI：10.1139/v66-350

  日期：1966.10.1

  During an investigation into the synthesis of optically active trityl systems, it was found that triphenylcarbinol could be converted into its methyl ether in an excellent yield by treatment with iodine in methanol. Although the reaction appeared to be an obvious one, a survey sho~ved that such a procedure had not as yet been recorded in the literature. I t became of interest, then, to study this ether-forming

  在对光学活性三苯甲基系统合成的研究中，发现通过用甲醇中的碘处理，可以将三苯基甲醇以极好的收率转化为其甲基醚。尽管反应似乎很明显，但一项调查表明，文献中尚未记录这种程序。于是，研究这种与其他芳基甲醇的醚形成反应就引起了人们的兴趣，这些芳基甲醇在我们的实验室中已经可用。表 I 显示了通过该程序合成的混合醚。尽管用标准硫代硫酸钠滴定表明碘是一种催化剂，但当它以大约等摩尔量使用时获得了最好的结果。将芳基甲醇溶解在丙酮和脂肪醇的混合物中，加入碘，
• Titanium(IV)-Mediated Ring-Opening/Dehydroxylative Cross-Coupling of Diaryl-Substituted Methanols with Cyclopropanol Derivatives
  作者：Si-Xuan Zhang、Yan Ding、Jun-Jie Wang、Chuanji Shen、Xiaocong Zhou、Xue-Qiang Chu、Mengtao Ma、Zhi-Liang Shen

  DOI：10.1021/acs.joc.1c01790

  日期：2021.11.5

  A titanium(IV)-mediated ring-opening/dehydroxylative cross-coupling of diaryl-substituted methanols with a cyclopropanol derivative was developed. The reactions proceeded efficiently to provide synthetically useful γ,γ-diaryl esters in moderate to good yields, which could be applied to the functionalization of complex molecules derived from bioactive fenofibrate and isoxepac and the synthesis of a

  开发了一种钛 (IV) 介导的二芳基取代的甲醇与环丙醇衍生物的开环/脱羟基交叉偶联。该反应有效地进行，以中等至良好的收率提供合成有用的 γ,γ-二芳基酯，可应用于衍生自生物活性非诺贝特和异恶唑的复杂分子的官能化以及唑洛夫特前体的合成。
• [EN] PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS<br/>[FR] DERIVES DE PYRAZOLE SERVANT DE MODULATEURS DE PROTEINE KINASE
  申请人：ASTEX TECHNOLOGY LTD

  公开号：WO2005061463A1

  公开（公告）日：2005-07-07

  The invention provides compounds of the formula: (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between Rl and NR2R3 and a maximum chain length of 4 atoms extending between E and NR2R3, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the inker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the NR2R3 group and provided that the oxo group when present is located at a carbon atom a with respect to the NR2R3 group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; Rl is an aryl or heteroaryl group; and R2, R3, R4 and R5 are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, methods for preparing the compounds and their use as anticancer agents.

  该发明提供了具有蛋白激酶B抑制活性的化合物，其化学式为：（I），其中A是一个饱和的含有1至7个碳原子的烷基链连接基团，该连接基团在R1和NR2R3之间延伸的最大链长为5个原子，在E和NR2R3之间延伸的最大链长为4个原子，其中连接基团中的一个碳原子可以选择性地被氧原子或氮原子取代；连接基团A的碳原子可以选择性地携带来自酮基、氟和羟基的一个或多个取代基，前提是当存在羟基时，该羟基不位于相对于NR2R3基团的碳原子a处，且当存在酮基时，该酮基位于相对于NR2R3基团的碳原子a处；E是一个单环或双环的碳环或杂环基团；R1是芳基或杂芳基团；R2、R3、R4和R5如权利要求中所定义。还提供了含有这些化合物的药物组合物，制备这些化合物的方法以及它们作为抗癌剂的用途。
• PHARMACEUTICAL COMBINATIONS COMPRISING PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS
  申请人：Thompson Neil Thomas

  公开号：US20100166699A1

  公开（公告）日：2010-07-01

  The invention provides a combination comprising an ancillary compound (e.g. one, two or more ancillary compounds) and a compound of the formula (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R 1 and NR 2 R 3 and a maximum chain length of 4 atoms extending between E and NR 2 R 3 , wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the NR 2 R 3 group and provided that the oxo group when present is located at a carbon atom a with respect to the NR 2 R 3 group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; R is an aryl or heteroaryl group; and R 2 , R 3 , R 4 and R 5 are as defined in the claims. Also provided are patient packs, pharmaceutical kits and packs and compositions containing the combinations, methods for preparing the combinations and their use in combination therapy as anticancer agents.

  该发明提供了一种组合物，包括一个辅助化合物（例如一个、两个或更多个辅助化合物）和具有蛋白激酶B抑制活性的式（I）化合物：其中A是含有1至7个碳原子的饱和碳氢链连接基团，连接基团在R1和NR2R3之间延伸的最大链长为5个原子，在E和NR2R3之间延伸的最大链长为4个原子，其中连接基团中的一个碳原子可以选择性地被氧原子或氮原子取代；连接基团A的碳原子可以选择性地携带来自酮基、氟和羟基的一个或多个取代基，前提是当羟基存在时，不位于相对于NR2R3基团的碳原子a处，且当酮基存在时，位于相对于NR2R3基团的碳原子a处；E是单环或双环碳环或杂环基团；R是芳基或杂芳基团；R2、R3、R4和R5如权利要求中所定义。还提供了患者包装、药物配套和包装以及含有这些组合物的组合物、制备这些组合物的方法以及它们作为抗癌剂的联合治疗中的用途。
• Pharmaceutical Compounds
  申请人：Davies Thomas Glanmor

  公开号：US20090253718A1

  公开（公告）日：2009-10-08

  The invention provides a compound having the formula (I): or salts, solvates, tautomers or N-oxides thereof, wherein T is N or CR 5 ; J 1 -J 2 is N═C(R 6 ), (R 7 )C═N, (R 8 )N—C(O), (R 8 ) 2 C—C(O), N═N or (R 7 )C═C(R 6 ); A is an optionally substituted saturated C 1-7 hydrocarbon linker group having a maximum chain length of 5 atoms extending between R 1 and NR 2 R 3 and a maximum chain length of 4 atoms extending between E and NR 2 R 3 , one of the carbon atoms in the linker group being optionally replaced by oxygen or nitrogen; E is a monocyclic or bicyclic carbocyclic or heterocyclic group or an acyclic group X-G wherein X is CH 2 , O, S or NH and G is a C 1-4 alkylene chain wherein one of the carbon atoms is optionally replaced by O, S or NH; R 1 is hydrogen or an aryl or heteroaryl group; R 2 and R 3 are each hydrogen, optionally substituted C 1-4 hydrocarbyl or optionally substituted C 1-4 acyl; or NR 2 R 3 forms an imidazole group or a saturated monocyclic heterocyclic group having 4-7 ring members; or NR 2 R 3 and A together form a saturated monocyclic heterocyclic group having 4-7 ring members which is optionally substituted by C 1-4 alkyl; or NR 2 R 3 and the adjacent carbon atom of linker group A together form a cyano group; or R 1 , A and NR 2 R 3 together form a cyano group; and R 4 , R 5 , R 6 , R 7 and R 8 are each independently selected from hydrogen and various substituents as defined in the claims, wherein the compound is for use in: (a) the treatment or prophylaxis of a disease or condition in which the modulation (e.g. inhibition) of ROCK kinase or protein kinase p70S6K is indicated; and/or (b) the treatment of a subject or patient population in which the modulation (e.g. inhibition) of ROCK kinase or protein kinase p70S6K is indicated.

  本发明提供了具有以下式子（I）的化合物或其盐，溶剂化物，互变异构体或N-氧化物，其中T为N或CR5; J1-J2为N═C（R6），（R7）C═N，（R8）N—C（O），（R8）2C—C（O），N═N或（R7）C═C（R6）; A为最大链长为5个原子的选择性取代的饱和C1-7碳氢链连接基，在R1和NR2R3之间延伸，最大链长为4个原子，在E和NR2R3之间延伸，链连接基中的一个碳原子可以被氧或氮取代; E为单环或双环的碳环或杂环基团或一个无环的X-G基团，其中X为CH2，O，S或NH，G为一个C1-4烷基链，其中一个碳原子可以被O，S或NH取代; R1为氢或芳基或杂环基团; R2和R3分别为氢，选择性取代的C1-4烃基或选择性取代的C1-4酰基; 或NR2R3形成咪唑基团或具有4-7个环成员的饱和单环杂环基团; 或NR2R3和A一起形成一个被C1-4烷基取代的饱和单环杂环基团; 或NR2R3和链连接基A的相邻碳原子一起形成氰基团; 或R1，A和NR2R3一起形成氰基团; R4，R5，R6，R7和R8各自独立地选择氢和各种在权利要求中定义的取代基，其中该化合物用于：（a）治疗或预防调节ROCK激酶或蛋白激酶p70S6K所示的疾病或情况; 和/或（b）治疗调节ROCK激酶或蛋白激酶p70S6K所示的受试者或患者人群。